ACADIA PHARMACEUTICALS INC
ACADIA PHARMACEUTICALS INC is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on December 22, 2026, a projected date rather than a confirmed one. There are 6 upcoming events on record.
ACADIA PHARMACEUTICALS INC generates cash from operations, so a burn-based runway figure does not apply.
Across 34 concluded trials, 71% reached completion rather than being terminated or withdrawn.
| Date | Event | Type | Phase |
|---|---|---|---|
| December 22, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| August 15, 2027 | ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response | Trial Milestone | Phase 2 |
| January 15, 2028 | ACP-204 in Adults With Alzheimer's Disease Psychosis | Trial Milestone | Phase 2/Phase 3 |
| February 15, 2028 | Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis | Trial Milestone | Phase 2 |
| February 15, 2029 | Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis | Trial Milestone | Phase 3 |
| April 15, 2029 | ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study | Trial Milestone | Phase 3 |
Track ACAD alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open ACAD in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.